Dorzolamide Hydrochloride API

Name	Dorzolamide hydrochloride
Chinese name	盐酸多佐胺
Cas Number	130693-82-2
Source	India
Qualifications	USDMF/-/-/-/-

Dorzolamide Hydrochloride was originally researched by Merck Pharmaceuticals and was approved for marketing in the United States in 1994. It was the first carbonic anhydrase inhibitor (CAI) approved by the FDA. Dorzolamide hydrochloride can strongly inhibit CA-Ⅱ, can act on the CA site of the eye, reduce the production of HCO3-, the osmotic pressure in aqueous humor, the production of aqueous humor, and the intraocular pressure; the dorzolamide hydrochloride can also It dilates blood vessels in the eye and has a positive effect on eye perfusion. Dorzolamide hydrochloride is a second-generation carbonic anhydrase inhibitor. Compared with acetazolamide and brinzolamide, it not only overcomes the systemic adverse reactions of oral medication, but is also easily soluble in water. It can be used as an aqueous solution and has adverse reactions. Lower. Orzalesi-N clinical research shows that dorzolamide hydrochloride lowers intraocular pressure at night than timolol. The photosensitivity test also shows that dorzolamide hydrochloride has a significant increase compared with timolol. According to IMS statistics, the domestic ophthalmic drug market has exceeded 20 billion yuan. In the past five years, China's ophthalmic prescription drug market has maintained a compound growth rate of 20%, which is a rapidly expanding drug market.

Hot Tags: dorzolamide hydrochloride api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Fulvestrant API, Bosentan API, Rasagiline Mesylate API, Letrozole API, Adapalene API, Tetrabenazine API

• Previous: Hydroxycobalamin Hydrochloride API
• Next: Trazodone Hydrochloride API